Development pathways for subcutaneous formulations of biologics versus biosimilar development
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Precision Medicine and Drug Development"
DOI: 10.1080/23808993.2019.1585806
Abstract: Introduction: Biologics are highly complex drugs and many of their characteristics are defined by the manufacturing process. In recent years, several monoclonal antibody (mAb) biologics, which were... read more here.
Keywords: subcutaneous formulations; pathways subcutaneous; development pathways; formulations biologics ... See more keywords